Výsledky vyhledávání - "James R. Rubinsak"

Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

Autor: F. Anthony Greco, Charles D. Webb, James A. Reeves, Elizabeth R. Vazquez, Howard A. Burris, Roger Inhorn, David R. Spigel, James R. Rubinsak, Dana S. Thompson, John D. Hainsworth, Cassie M. Lane

Publikováno v: Clinical Lung Cancer. 11:198-203

Background Targeting epidermal growth factor receptors (EGFRs) has been a novel strategy in treating non–small-cell lung cancer (NSCLC). This multicenter, community-based trial was designed to examine the role of cetuximab in combination with a non

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eecde644ba9a4ced4e1903510c9e4a7f
https://doi.org/10.3816/clc.2010.n.026

Zobrazit plný text záznamu

Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide

Autor: James R. Rubinsak, James M. Thompson, Ronald Halvorson, Michael J. Snyder, Robert Johnson, James H. Essell, Glenn S. Harman

Publikováno v: Blood. 79:2784-2788

The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1bf0fb6027f04ed5b4125bc30bc813e2
https://doi.org/10.1182/blood.v79.10.2784.2784

Zobrazit plný text záznamu

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial

Autor: Suzanne F. Jones, F. Anthony Greco, Howard A. Burris, David R. Spigel, James R. Rubinsak, Emily R. Burkett, Natalie R. Dickson, Melodie Thomas, Daniel C. Scullin, Joseph E. Brierre, Denise A. Yardley, John D. Hainsworth, James E. Bradof

Publikováno v: Clinical lung cancer. 7(2)

BACKGROUND: Patients with advanced non–small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS: Seventy-two patients with p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1741cf04deea854e4283a69b19ecd2c
https://pubmed.ncbi.nlm.nih.gov/16179100

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání